Skip to main content
. 2025 Jul 23;17(7):e88575. doi: 10.7759/cureus.88575

Table 1. Immunophenotypic features and differential diagnoses of pediatric-type diffuse low-grade gliomas.

MYB: V-myb avian myeloblastosis viral oncogene homolog; MYBL1: V-myb avian myeloblastosis viral oncogene homolog-like 1; IDH1: Isocitrate dehydrogenase 1; GFAP: Glial fibrillary acidic protein; ATRX: Alpha-Thalassemia mental retardation syndrome X-linked; BRAF: B-Raf proto-oncogene, serine/threonine kinase; Olig-2: Oligodendrocyte lineage transcription factor 2; EMA: Epithelial membrane antigen; CD34: Cluster of Differentiation 34, MN-1: Meningioma 1 proto-oncogene; H3F3A G34R/V: H3.3 histone A, mutation where glycine at position 34 is replaced by arginine [R] or valine [V]; H3K27M: surrogate immunomarker for mutation in H3F3A or HIST1H3B/C gene where lysine 27 is replaced by methionine; DNET: Dysembryoplastic neuroepithelial tumor

Tumor Type Marker Result/Status Differentials
Diffuse Astrocytoma, MYB/MYBL1-Altered IDH1 p.R132H Negative Astrocytoma, IDH-mutant
GFAP Positive Astrocytoma, IDH-wild type
ATRX Retained expression Angiocentric glioma
EMA Dot-like intracytoplasmic [14] Ganglioglioma
CD34 Negative CD34-negative gliomas
Ki-67 Proliferation Index < 1% Low proliferative index gliomas
Angiocentric Glioma IDH1 p.R132H Negative Astroblastoma, MN-1, altered
GFAP Positive Astrocytoma, IDH-mutant
EMA Perinuclear dot-like Astrocytoma, IDH-wild type
Olig-2 Negative Ependymoma
Ki-67 Proliferation Index < 1–5% [16,18,20] Low-grade glioma
Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY) IDH1 p.R132H Negative Astroblastoma, MN-1, altered
GFAP Positive Astrocytoma, IDH-mutant
Olig-2 Positive Astrocytoma, IDH-wild type
CD34 Positive Ependymoma
ATRX Retained expression ATRX-retained gliomas
BRAFp.V600E Positive (in up to 54% of cases)[19, 45-48] BRAF-mutant low-grade gliomas
Diffuse Low-Grade Glioma, MAPK Pathway-Altered IDH1 p.R132H Negative Pilocytic astrocytoma
GFAP Positive DNET 
Olig-2 Positive Ganglioglioma
BRAFp.V600E Positive BRAF-driven tumors
H3F3A G34R/V Negative Excludes G34R/V mutant gliomas
H3K27M Negative Excludes midline glioma, H3K27-altered